(MENAFN- GlobeNewsWire - Nasdaq) The report identifies opportunities for strategic investment decisions and competitive advantage in the global MASH/NASH clinical trials landscape, highlighting key regions, trial phases, and sponsor types. It aids in pinpointing cost-effective trial locations and understanding enrollment trends and trial success rates.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets's offering.
This report provides top line data relating to the clinical trials on Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Report Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

• Report Guidance
• The analyst Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) to Gastrointestinal Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Therapeutics Clinical Trials
• Prominent Drugs

Latest Clinical Trials News on Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)

• Oct 20, 2025: Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Poster at AASLD The Liver Meeting 2025
• Oct 15, 2025: Rivus Pharmaceuticals To Present Clinical Data From Phase 2A M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD 2025
• Oct 07, 2025: Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting 2025
• Oct 07, 2025: Akero Therapeutics To Present New Data From the Phase 2B Symmetry and Harmony Studies of Efruxifermin at the 76th Annual AASLD the Liver Meeting 2025
• Oct 07, 2025: Sagimet Biosciences Announces Upcoming Presentation at AASLD-the Liver Meeting 2025
• Oct 07, 2025: Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
• Oct 06, 2025: Eccogene Receives U.S. FDA Clearance To Initiate Phase 2A Mosaic Trial of ECC4703 for MASH
• Oct 06, 2025: Eccogene Receives U.S. FDA Clearance To Initiate Phase 2A MOSAIC Trial of ECC0509 for MASH
• Oct 01, 2025: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
• Sep 17, 2025: Positive Phase 3 Results for Denifanstat for the Treatment of Moderate To Severe Acne To Be Presented at the EADV Congress 2025 by Partner Ascletis
• Sep 02, 2025: Biomed Industries to Present Pivotal Studies on NA-931 at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
• Sep 02, 2025: Biomed Industries to Present Pivotal Studies on NA-941 at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
• Aug 14, 2025: Akero Announces Publication of Phase 2b Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
• Aug 12, 2025: Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH
• Aug 11, 2025: Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Companies Featured

• Pfizer Inc
• ICON Plc
• AstraZeneca Plc
• Thermo Fisher Scientific Inc
• Labcorp Holdings Inc
• The Nucleus Network Pty Ltd
• C. H. Boehringer Sohn AG & Co KG
• Gilead Sciences Inc
• Novo Nordisk AS
• Novartis AG

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01122025004107003653ID1110420305